FDA Grants Accelerated Approval to Etcamah for Resistant Advanced Breast Cancer

The U.S. Food and Drug Administration approved Etcamah under its accelerated pathway, citing trial data where patients experienced a median 16-month interval before cancer worsened, versus 9.2 months on existing hormone therapy. The medication is intended for adult patients with HR-positive, HER2-negative breast cancer that has metastasized, and is administered together with CDK4/6 inhibitors. A newly authorized blood test, Guardant360 CDx, identifies ESR1 gene changes that cause resistance, enabling clinicians to switch to Etcamah before imaging shows tumor growth.

Breast oncologist Donna McNamara described the approval as a transformative, proactive step in precision oncology, while emphasizing that regulators still await mature data on overall survival and that the drug can cause serious side effects such as heart arrhythmia. AstraZeneca’s Dave Fredrickson highlighted the combination as the first of its kind in the first-line setting, and further studies are planned to verify long-term benefits.